ProStrakan Group plc
http://www.prostrakan.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ProStrakan Group plc
Pathalys Raises $105m To Pave Path Toward US Commercialization
The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.
Bayer Moves Closer To Astellas With Menopause Drug Filing
As sales of the Japanese drugmaker’s non-hormonal treatment for menopausal symptoms Veozah finally take off, the German major has filed its potential competitor, elinzanetant, with the US Food and Drug Administration.
Soterios Topical Could Take On JAK Class In Alopecia Areata
The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.
Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Strakan Pharmaceuticals, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice